

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## 上海復旦張江生物醫藥股份有限公司

**Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code:1349)**

### **ESTIMATED RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022**

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that based on the information currently available to the Company and the preliminary assessment from the Company’s management of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 (the “**Reporting Period**”), it is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB-40 million to RMB-30 million during the Reporting Period (corresponding period in 2021: unaudited net profit attributable to shareholders of the Company of RMB65.48 million), representing a loss over the corresponding period in 2021. The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB-50 million to RMB-40 million (corresponding period in 2021: unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB54.54 million).

As far as the Board is aware, the decline in performance for the Reporting Period as compared to the corresponding period in 2021 was mainly attributable to the following:

- (i) Since March 2022, the situation of the COVID-19 epidemic (the “**Epidemic**”) in Shanghai has been severe, and in accordance with the Epidemic prevention and control policy, the whole region has gradually implemented static management, which causes certain difficulties to the normal development of the Company's production, operation and research and development projects. In addition, the control on the external logistics has a great impact on the Company's raw materials supply and external drug distribution. As a result, the production and delivery of products cannot be completed as planned. The Epidemic subsided and the whole-region-wide static management in Shanghai was

gradually lifted in June, and the Company gradually resumed the production and operation. Although the Group actively organized production and logistics with good Epidemic precautions to minimize the impact of the Epidemic, and strived to compensate during June, the Company still recorded a decrease in revenues as compared to that in 2021, resulting in a decrease in other relevant financial data;

- (ii) The Company implemented the 2021 Restricted Shares Incentive Scheme to establish and improve the Company's long-term incentive mechanism, attract and retain the Company's management personnel, core technical personnel and other personnel, fully mobilize their enthusiasm and creativity. The share-based payments recognized during the Reporting Period were approximately RMB50.50 million. If excluding the impact of above-mentioned share-based payment expenses, the net profit attributable to shareholders of the Company during the Reporting Period would be approximately RMB10.50 million to RMB20.50 million, and the net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss would be approximately RMB0.50 million to RMB10.50 million. There was no such expense in the same period of 2021.

As at the date of this announcement, the Company is still in the process of preparing the interim results of the Group for the six months ended 30 June 2022. The information set out above is only based on a preliminary assessment by the Board with reference to the information currently available to it (including the consolidated management accounts which have not been finalized or reviewed by the Company's auditors or the audit committee). The interim results of the Group for the six months ended 30 June 2022 is expected to be published in late August 2022. Further announcement(s) will be made by the Company in due course if there is any update in this regard.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board

**Wang Hai Bo**

*Chairman*

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

15 August 2022

*\* For identification purpose only*